Dermira Inc (DERM1)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Thomas G. Wiggans
Employees:
333
275 MIDDLEFIELD ROAD, SUITE 150, MENLO PARK, CA 94025
650 421 7200

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Dermira, Inc. is a biopharmaceutical company that focuses on bringing differentiated products to dermatologists and patients. It also focuses on medical dermatology, a field that concentrates on therapeutic solutions to treat skin conditions, such as psoriasis, hyperhidrosis and acne. Dermira was founded by Thomas G. Wiggans, Eugene Andrew Bauer, Luis C. Peña, and Christopher M. Griffith on August 18, 2010 and is headquartered in Menlo Park, CA.

Data derived from most recent annual or quarterly report
Market Cap 1.026 Billion Shares Outstanding54.695 Million Avg 30-day Volume 2.152 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-3.57
Price to Revenue4.1946 Debt to Equity24.4762 EBITDA-194.286 Million
Price to Book Value24.0066 Operating Margin-246.9948 Enterprise Value341.868 Million
Current Ratio7.035 EPS Growth0.089 Quick Ratio6.296
1 Yr BETA 1.5147 52-week High/Low 0.0 / Profit Margin-256.0846
Operating Cash Flow Growth-29.279 Altman Z-Score-2.6762 Free Cash Flow to Firm -207.133 Million
View SEC Filings from DERM1 instead.

View recent insider trading info

Funds Holding DERM1 (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding DERM1 BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

CRAVES FRED B

0 2020-02-20 0

WIGGANS THOMAS G CEO & CHAIRMAN OF THE BOARD

0 2020-02-20 0

BAUER EUGENE A CHIEF MEDICAL OFFICER

0 2020-02-20 0

GUGGENHIME ANDREW CFO

0 2020-02-20 0

RINGO WILLIAM R

0 2020-02-20 0

MCDADE MARK

0 2020-02-20 0

COHEN DAVID E

0 2020-02-20 0

FUST MATTHEW K

0 2020-02-20 0

NUNN JASON RALEIGH

0 2020-02-20 0

GILBERT HALLEY E

0 2020-02-20 0

GRIFFITH CHRISTOPHER M. CHIEF BUSINESS & STRATEGY OFF

0 2020-02-20 0

PENA LUIS C. CHIEF DEVELOPMENT OFFICER

0 2020-02-20 0

SEBELIUS KATHLEEN

0 2020-02-20 0

LYONS-WILLIAMS LORI CHIEF COMMERCIAL OFFICER

0 2020-02-20 0

HORAN CHRISTOPHER CHIEF TECHNICAL OPS OFFICER

0 2020-02-20 0

AURORA DALJIT SINGH CHIEF SCIENTIFIC AFFAIRS OFF

0 2020-02-20 0

BALD EAGLE ACQUISITION CORP

ELI LILLY & CO

  • 10% Owner
0 2020-01-10 0

CAEYMAEX EMMANUEL

  • Director
0 2016-12-21 0

CANAAN VIII LP

CANAAN PARTNERS VIII LLC

  • Director
1,500,089 2015-11-30 0

HUTTON WENDE S

  • Director
0 2015-06-11 0

BARRIS PETER J

  • 10% Owner
17,241 2014-10-02 0

BARRETT M JAMES

  • 10% Owner
17,241 2014-10-02 0

MOTT DAVID M

  • 10% Owner
17,241 2014-10-02 0

KERINS PATRICK J

  • 10% Owner
17,241 2014-10-02 0

SANDELL SCOTT D

  • 10% Owner
17,241 2014-10-02 0

KOLLURI KRISHNA KITTU

  • 10% Owner
17,241 2014-10-02 0

BASKETT FOREST

  • 10% Owner
17,241 2014-10-02 0

BAY CITY CAPITAL LLC

BAY CITY CAPITAL MANAGEMENT V LLC

BAY CITY CAPITAL FUND V, L.P.

BAY CITY CAPITAL FUND V CO-INVESTMENT FUND, L.P.

  • Director
  • 10% Owner
17,240 2014-10-02 0

DRANT RYAN D

  • 10% Owner
17,241 2014-10-02 0

WELLER HARRY R

  • 10% Owner
17,241 2014-10-02 0

NEW ENTERPRISE ASSOCIATES 13 LP

NEA 13 GP, LTD

NEA PARTNERS 13, LIMITED PARTNERSHIP

  • 10% Owner
17,241 2014-10-02 0

VISWANATHAN RAVI

  • 10% Owner
17,241 2014-10-02 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments